Building on the momentum of GLP-1 programs in OSA, Sleepiz One+ replaces burdensome, complex and costly PSG assessments. CE-marked for OSA in the EU and pursuing US pathways, it shows high concordance with PSG, supports primary and secondary OSA endpoints, reduces trial cost and burden, and accelerates label expansion.

Rare diseases demand zero-burden measurement. Sleepiz One+ is fully contactless, ideal for mobility-impaired populations, delivering nightly real-world data on breathing and sleep without patient interaction. With DEEP’s structured evidence model and a CE mark, sponsors gain meaningful endpoints, improved feasibility and retention, and clear pathways to regulatory alignment.

COPD, asthma, and IPF are 24-hour conditions, yet trials rarely capture night. Sleepiz One+ provides contactless, continuous, at-home measures of respiration and sleep quality, producing longitudinal, objective evidence of nocturnal control. CE-marked and integrated with DEEP, it enables novel endpoints, strengthens labels, and demonstrates round-the-clock therapeutic benefit.

This DEEP pilot centers on engaging with NICE through the scientific advice service with the goal of identifying where digital endpoints may fall short of current HTA expectations—and how to address those gaps proactively.

Advance the use of voice digital biomarkers for early prediction of COPD Heart Failure.

Extend the work of public-private partnerships to achieve regulatory acceptance of digital mobility measures in COPD

Extend the work of public-private partnerships to achieve regulatory acceptance of digital mobility measures in Parkinson's disease.

Accelerate clinical validation and regulatory acceptance of digital measures for nocturnal scratching in Atopic Dermatitis and Psoriasis, building on prior DEEP work and seeking input from relevant authorities (FDA, EMA)

Extend the work of public-private partnerships and relevant research initiatives to achieve regulatory acceptance of digital pain & mobility measures in rheumatoid arthritis.

Solutions for wrist-worn actigraph already exist in Atopic dermatitis, more work needs to be done to extend these solutions into Psoriasis.

​

Extend DiMe and IMI RADAR-AD work on digital measures for ADRD. Curate findings, develop TSPs, and pursue regulatory acceptance through DEEP collaboration.

Accelerate development of digital measures for early CRS detection. Align on models & standards for wearable sensors in oncology.

We are currently exploring how technology could be used to develop a precise and comprehensive digital measure for MG – taking into consideration various relevant modalities such as vision, speech, swallowing, and physical activity – that could complement existing traditional measures like the MG-ADL. We are seeking clinical expertise in these early conceptual stages in parallel with a review of the literature for gaps in the digital healthcare scenery in MG.